Dewey Steadman

Analyst Dewey Steadman is focused on the Healthcare sector with 98 price targets and ratings documented since 2016 spanning on 7 stocks. Previously, Dewey Steadman worked at CANACCORD. Analyst's average stock valuation to be materialised ratio is 53.62% with an average time for price targets to be met of 119.17 days.

Most recent stock forecast was given on AERI, Aerie Pharmaceuticals, Inc at 11-Jun-2019.

Dewey Steadman best performing recommendations are on ANIP (ANI PHARMACEUTICALS, INC).
The best stock recommendation documented was for MNK at 11/8/2017. The price target of $24 was fulfilled within 34 days with a profit of $4.02 (20.12%) receiving and performance score of 5.92.

Average potential price target upside

• of $11.89 (20.91%) on ANIP (ANI PHARMACEUTICALS, INC).
• of $10.59 (21.25%) on AERI (AERIE PHARMACEUTICALS, INC).
• of $6.16 (15.24%) on PCRX (PACIRA BIOSCIENCES, INC).